A novel imaging-compatible sciatic nerve schwannoma model

Journal of Neuroscience Methods

Volumn 195, Issue 1, 2011, Pages 75-77

  Saydam, Okay ^a   Ozdener, Gokhan Baris ^a   Senol, Ozlem ^a   Mizrak, Arda ^a   Prabhakar, Shilpa ^a   Stemmer Rachamimov, Anat O ^a   Breakefield, Xandra O ^a   Brenner, Gary J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

NF2; Schwannoma; Sciatic nerve tumor model

Indexed keywords

LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL IMMORTALIZATION; CELL LINE; FEMALE; FLUORESCENCE; IMAGING; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; LUCIFERASES, FIREFLY; LUMINESCENT PROTEINS; MICE; MICE, NUDE; NEURILEMMOMA; SCIATIC NERVE; TRANSDUCTION, GENETIC;

EID: 78650933130     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.10.021     Document Type: Article

References (11)

1. Badr C.E., Hewett J.W., Breakefield X.O., Tannous B.A. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS One 2007, 2:e571.
2. Boyd C., Smith M.J., Kluwe L., Balogh A., Maccollin M., Plotkin S.R. Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet 2008, 74:358-366.
3. Brenner G.J., Ji R.R., Shaffer S., Woolf C.J. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci 2004, 20:375-384.
4. Giovannini M., Robanus-Maandag E., Niwa-Kawakita M., van der Valk M., Woodruff J.M., Goutebroze L., et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev 1999, 13:978-986.
5. Giovannini M., Robanus-Maandag E., van der Valk M., Niwa-Kawakita M., Abramowski V., Goutebroze L., et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev 2000, 14:1617-1630.
6. Hung G., Li X., Faudoa R., Xeu Z., Kluwe L., Rhim J.S., et al. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 2002, 20:475-482.
7. Jones G.N., Tep C., Towns W.Hn., Mihai G., Tonks I.D., Kay G.F., et al. Tissue-specific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 2008, 10:1213-1221.
8. MacCollin M., Chiocca E.A., Evans D.G., Friedman J.M., Horvitz R., Jaramillo D., et al. Diagnostic criteria for schwannomatosis. Neurology 2005, 64:1838-1845.
9. Martuza R.L., Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988, 318:684-688.
10. Messerli S.M., Prabhakar S., Tang Y., Mahmood U., Weissleder R., Bronson R., et al. Treatment of schwannomas with an oncolytic HSV recombinant virus in murine models of neurofibromatosis type 2. Hum Gene Ther 2006, 17:20-30.
11. Saydam O., Shen Y., Würdinger T., Senol O., Boke E., James M.F., et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/{beta}-catenin signaling pathway. Mol Cell Biol 2009, 29:5923-5940.